The New Credit Agreement, effective as of the closing date, involves various lenders, including funds managed by Blue Owl Capital and Blackstone, with Blue Owl Capital Corporation serving as the administrative agent. This collaboration is expected to provide Caris with the necessary liquidity to navigate the competitive landscape of the life sciences sector.
In addition to the initial term loan, the agreement features a committed delayed draw term loan facility of up to $300 million, which can be accessed in multiple tranches. This flexibility is designed to support Caris in pursuing strategic acquisitions and investments that align with its growth objectives. Furthermore, the agreement includes an uncommitted incremental facility of up to $500 million, providing additional financial resources as needed.
The terms of the financing include competitive interest rates, with options for the company to choose between the Term SOFR Rate or Base Rate, plus an additional margin. This structure is designed to optimize Caris's cost of capital while ensuring that it can effectively manage its debt obligations.
The New Credit Agreement also incorporates standard covenants and conditions, including requirements for maintaining a minimum level of qualified cash and restrictions on certain financial activities. These provisions are intended to safeguard the interests of the lenders while allowing Caris to maintain operational flexibility.
Overall, this financing agreement is a strategic move for Caris Life Sciences, positioning the company for future growth and operational success. The infusion of capital is expected to enhance its ability to innovate and expand its offerings in the life sciences market, ultimately benefiting stakeholders and investors alike.
